Sionna chooses Phase 2a cystic fibrosis drug after healthy volunteer studynews2025-06-04T11:00:09+00:00June 4th, 2025|Endpoints News|
Eli Lilly inks deal with Camurus for its long-acting obesity technews2025-06-04T10:42:09+00:00June 4th, 2025|Endpoints News|
#ASCO25: BioNTech presents impressive early data for PD-L1xVEGF in mesotheliomanews2025-06-03T12:00:23+00:00June 3rd, 2025|Endpoints News|
#ASCO25: Brain cancer cell therapies make early stridesnews2025-06-03T10:00:45+00:00June 3rd, 2025|Endpoints News|
Lyra’s stock soars on Phase 3 success for chronic rhinosinusitis treatmentnews2025-06-02T16:39:16+00:00June 2nd, 2025|Endpoints News|
Regeneron makes $80M obesity deal with Hansohnews2025-06-02T15:11:14+00:00June 2nd, 2025|Endpoints News|
Phase 3 or bust: Why Lilly won’t run mid-stage cancer trialsnews2025-06-02T12:00:19+00:00June 2nd, 2025|Endpoints News|
#ASCO25: Enhertu combo has the makings of a new standard in HER2-positive breast cancernews2025-06-02T12:00:10+00:00June 2nd, 2025|Endpoints News|
Sanofi to snap up Blueprint Medicines and mastocytosis drug Ayvakit for $9.1Bnews2025-06-02T11:20:21+00:00June 2nd, 2025|Endpoints News|
Kymera reports Phase 1 data for pill to rival Dupixentnews2025-06-02T11:00:03+00:00June 2nd, 2025|Endpoints News|
